Bortecade Dosage/Direction for Use

Recommended Dosage: The recommended dose of Bortecade is 1.3 mg/m²/dose administered as a 3 to 5 second bolus intravenous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12-21). This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of Bortecade. It is recommended that patients with a confirmed complete response receive 2 additional cycles of Bortecade beyond a confirmation. It is also recommended that responding patients who do not achieve a complete remission receive a total of 8 cycles of Bortecade therapy.
Dose Modification and Reinitiation of Therapy: Bortecade therapy should be withheld at the onset of any Grade 3 non-hematological or Grade 4 hematological toxicities excluding neuropathy as discussed as follows (see Precautions).
Once the symptoms of the toxicity have resolved, Bortecade therapy may be reinitiated at a 25% reduced dose (1.3 mg/m²/dose reduced to 1.0 mg/m²/dose; 1.0 mg/m²/dose reduced to 0.7 mg/m²/dose). The following table contains the recommended dose modification for the management of patients who experience Bortecade-related neuropathic pain and/or peripheral sensory neuropathy (Table 1). Patients with pre-existing severe neuropathy should be treated with Bortecade only after careful risk/benefit assessment. (See Table 1.)


Click on icon to see table/diagram/image


Administration: Bortecade is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with 0.9% sodium chloride solution for injection. The safety and effectiveness of Bortezomib in children has not been established.